NO2721710T3 - - Google Patents

Info

Publication number: NO2721710T3
Authority: NO; Norway

Application number

NO12803361A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-21

Filing date

2012-06-19

Publication date

2018-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2721710(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-19 Application filed filed Critical

2018-03-31 Publication of NO2721710T3 publication Critical patent/NO2721710T3/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N7/00—Television systems
- H04N7/18—Closed-circuit television [CCTV] systems, i.e. systems in which the video signal is not broadcast
- H04N7/188—Capturing isolated or intermittent images triggered by the occurrence of a predetermined event, e.g. an object reaching a predetermined position

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Hematology (AREA)
Cardiology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)

NO12803361A 2014-08-21 2012-06-19 NO2721710T3 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462039969P	2014-08-21	2014-08-21

Publications (1)

Publication Number	Publication Date
NO2721710T3 true NO2721710T3 (de)	2018-03-31

Family

ID=54148580

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO12803361A NO2721710T3 (de)	2014-08-21	2012-06-19

Country Status (48)

Country	Link
US (5)	US9663526B2 (de)
EP (1)	EP3183247B9 (de)
JP (1)	JP6218260B2 (de)
KR (1)	KR101877189B1 (de)
CN (1)	CN107074867B (de)
AP (1)	AP2017009748A0 (de)
AR (1)	AR101599A1 (de)
AU (1)	AU2015304883B2 (de)
BR (1)	BR112017003054B1 (de)
CA (1)	CA2900855C (de)
CL (1)	CL2017000406A1 (de)
CO (1)	CO2017001603A2 (de)
CR (1)	CR20170066A (de)
CU (1)	CU24435B1 (de)
CY (1)	CY1119771T1 (de)
DK (1)	DK3183247T3 (de)
DO (1)	DOP2017000048A (de)
EA (1)	EA032609B1 (de)
EC (1)	ECSP17010156A (de)
ES (1)	ES2655971T3 (de)
GE (1)	GEP20197003B (de)
GT (1)	GT201700035A (de)
HR (1)	HRP20171913T1 (de)
HU (1)	HUE035553T2 (de)
IL (1)	IL250709B (de)
LT (1)	LT3183247T (de)
MA (1)	MA40587A (de)
MD (1)	MD4800C1 (de)
ME (1)	ME02856B (de)
MX (1)	MX2017002241A (de)
MY (1)	MY192109A (de)
NI (1)	NI201700020A (de)
NO (1)	NO2721710T3 (de)
NZ (1)	NZ729005A (de)
PE (1)	PE20171177A1 (de)
PH (1)	PH12017500276A1 (de)
PL (1)	PL3183247T3 (de)
PT (1)	PT3183247T (de)
RS (1)	RS56807B1 (de)
SG (1)	SG11201700957WA (de)
SI (1)	SI3183247T1 (de)
SV (1)	SV2017005384A (de)
TN (1)	TN2017000044A1 (de)
TW (1)	TWI583681B (de)
UA (1)	UA117976C2 (de)
UY (1)	UY36275A (de)
WO (1)	WO2016027195A1 (de)
ZA (1)	ZA201701005B (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2325171B1 (de)	2005-05-26	2013-10-09	Aldexa Therapeutics, Inc.	Chinolinderivate zur Behandlung retinaler Erkrankungen
JP5885670B2 (ja)	2009-12-11	2016-03-15	アルデイラセラピューティクス，インコーポレイテッド	黄斑変性の処置のための組成物および方法
SG11201505587YA (en)	2013-01-23	2015-08-28	Aldeyra Therapeutics Inc	Toxic aldehyde related diseases and treatment
JP6577958B2 (ja)	2014-04-11	2019-09-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用
EP3164401B1 (de)	2014-07-03	2018-12-26	Boehringer Ingelheim International GmbH	Neue spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one verbindungen und deren derivate als mdm2-p53 inhibitoren
HUE046057T2 (hu)	2014-08-21	2020-02-28	Boehringer Ingelheim Int	Új spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és származékok, mint MDM2-P53-inhibitorok
NO2721710T3 (de)	2014-08-21	2018-03-31
CN118724806A (zh)	2015-08-21	2024-10-01	奥尔德拉医疗公司	氘化化合物和其用途
WO2017044434A1 (en)	2015-09-11	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
DK3359542T3 (da)	2015-10-09	2021-05-31	Boehringer Ingelheim Int	Spiro[3h-indol-3,2'-pyrrolidin]-2(1h)-on-forbindelser og derivater som mdm2-p53-inhibitorer
AU2017258186B2 (en) *	2016-04-28	2020-09-17	Theravance Biopharma R&D Ip, Llc	Pyrimidine compounds as JAK kinase inhibitors
AU2017264697A1 (en)	2016-05-09	2018-11-22	Aldeyra Therapeutics, Inc.	Combination treatment of ocular inflammatory disorders and diseases
US10111882B2 (en)	2016-09-14	2018-10-30	Gilead Sciences, Inc.	SYK inhibitors
TW201822764A (zh)	2016-09-14	2018-07-01	美商基利科學股份有限公司	Syk抑制劑
TWI825663B (zh)	2016-10-14	2023-12-11	美商林伯士拉克許米公司	Tyk2抑制劑及其用途
MX2019010576A (es)	2017-03-16	2019-10-07	Aldeyra Therapeutics Inc	Compuestos polimorficos y usos de los mismos.
WO2018195471A1 (en)	2017-04-21	2018-10-25	Gilead Sciences, Inc.	Syk inhibitors in combination with hypomethylating agents
CN108864057B (zh) *	2017-05-16	2020-03-31	山东大学	含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
CN109422753B (zh) *	2017-09-03	2021-12-31	上海美志医药科技有限公司	一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
CN111356451A (zh)	2017-10-10	2020-06-30	奥尔德拉医疗公司	炎性病症的治疗
CR20200180A (es) *	2017-10-27	2020-08-12	Theravance Biopharma R&D Ip Llc	Compuesto de pirimidina como inhibidor de las janocinasas
US10683297B2 (en)	2017-11-19	2020-06-16	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
SG11202007422QA (en)	2018-02-05	2020-09-29	Alkermes Inc	Compounds for the treatment of pain
JPWO2020017569A1 (ja)	2018-07-17	2021-12-02	日本ケミファ株式会社	Ｔ型カルシウムチャネル阻害剤
CN112714762A (zh)	2018-08-06	2021-04-27	奥尔德拉医疗公司	多晶型化合物及其用途
WO2020068846A1 (en) *	2018-09-25	2020-04-02	Heterocyclic Compound	Heterocyclic compound
CN113365632B (zh)	2018-09-25	2024-03-08	卡都瑞恩医药有限公司	氨基嘧啶化合物
GB201816369D0 (en)	2018-10-08	2018-11-28	Sareum Ltd	Pharmaceutical compounds
CN109364248B (zh) *	2018-10-16	2021-05-18	哈尔滨医科大学	ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
AR116592A1 (es) *	2018-10-17	2021-05-26	Lilly Co Eli	Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
CN113646310A (zh)	2019-02-15	2021-11-12	辉瑞公司	结晶性的嘧啶基-3,8-二氮杂双环[3.2.1]辛烷基甲酮化合物及其用途
CN111658628B (zh) *	2019-03-08	2022-03-01	中国科学院动物研究所	Gli2抑制剂的用途以及抑制gli2的化合物的筛选方法
WO2020182159A1 (zh)	2019-03-14	2020-09-17	上海华汇拓医药科技有限公司	Jak激酶抑制剂及其制备方法和在医药领域的应用
KR20210142154A (ko)	2019-03-21	2021-11-24	옹쎄오	암 치료를 위한 키나제 억제제와 조합된 dbait 분자
AU2020250468A1 (en)	2019-03-29	2021-11-04	Kinki University	Use of T-type calcium channel blocker for treating pruritus
CA3135388A1 (en)	2019-04-24	2020-10-29	Theravance Biopharma R&D Ip, Llc	Pyrimidine jak inhibitors for the treatment of skin diseases
HRP20240346T1 (hr)	2019-04-24	2024-05-24	Theravance Biopharma R&D Ip, Llc	Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze
JP2022537877A (ja)	2019-04-30	2022-08-31	セルジーンコーポレイション	アプレミラストおよびｔｙｋ２阻害剤を含む併用療法
US12098132B2 (en)	2019-05-02	2024-09-24	Aldeyra Therapeutics, Inc.	Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja)	2019-05-02	2022-07-05	アルデイラセラピューティクス，インコーポレイテッド	多形化合物およびその使用
KR20220046593A (ko) *	2019-08-09	2022-04-14	더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드	가교된 헤테로사이클일-치환된 피리미딘 화합물, 이의 제조 방법, 및 이의 약학 용도
AU2020347561A1 (en) *	2019-09-11	2022-04-14	Pfizer Inc.	Treatment of hidradenitis with JAK inhibitors
US11992490B2 (en)	2019-10-16	2024-05-28	Incyte Corporation	Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN110862376A (zh) *	2019-10-24	2020-03-06	嘉兴特科罗生物科技有限公司	一种小分子化合物
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN113372364B (zh) *	2020-03-10	2024-05-31	明慧医药（上海）有限公司	一类jak激酶抑制剂及其制备和应用
KR20220154722A (ko) *	2020-03-17	2022-11-22	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	융합된 이환식 유도체, 이의 제조 방법, 및 이의 약학적 용도
CN115715194A (zh)	2020-04-04	2023-02-24	辉瑞公司	治疗冠状病毒疾病2019的方法
GB202005114D0 (en)	2020-04-07	2020-05-20	Sareum Ltd	Crystalline Forms of a Pharmaceutical Compound
CN111423420A (zh) *	2020-04-30	2020-07-17	广州博济医药生物技术股份有限公司	作为己酮糖激酶抑制剂的并环化合物
CA3175856A1 (en)	2020-05-13	2021-11-18	Todd Brady	Pharmaceutical formulations and uses thereof
CN113698403B (zh) *	2020-05-21	2022-06-28	南京亘泰医药技术有限公司	(1r,4r,7r)-7-氨基-2-氮杂双环[2,2,1]庚烷衍生物及制备方法
WO2021249367A1 (zh) *	2020-06-09	2021-12-16	苏州晶云药物科技股份有限公司	二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
TWI785660B (zh)	2020-07-02	2022-12-01	美商輝瑞大藥廠	嘧啶基-3,8-二氮雜雙環[3.2.1]辛烷基甲酮衍生物及其鹽之製備
TWI782599B (zh)	2020-07-02	2022-11-01	美商輝瑞股份有限公司	胺基嘧啶基衍生物
CA3189561A1 (en)	2020-07-17	2022-01-20	Pfizer Inc.	Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological conditions
EP4211171A2 (de)	2020-09-10	2023-07-19	Precirix N.V.	Antikörperfragment gegen fap
CN115087640B (zh) *	2021-01-14	2024-11-05	中国医药研究开发中心有限公司	桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
CN114835717A (zh) *	2021-02-01	2022-08-02	杭州领业医药科技有限公司	Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
MX2023009857A (es)	2021-03-15	2024-01-03	Maze Therapeutics Inc	Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos.
CN113698409B (zh) *	2021-08-10	2022-07-19	上海凌凯医药科技有限公司	一种多用途的二氮杂双环类化合物、制备方法及在合成药物中的应用
CN113999239B (zh) *	2021-07-14	2022-11-11	上海凌富药物研究有限公司	一种二氮杂桥化合物的合成方法
CN113461687B (zh) *	2021-08-10	2022-04-19	四川大学华西医院	2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途
EP4403550A1 (de) *	2021-09-17	2024-07-24	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Kondensiertes bicyclisches derivat, pharmazeutisch unbedenkliches salz, kristalline form davon und herstellungsverfahren dafür
AU2022378463A1 (en)	2021-10-25	2024-05-09	Kymera Therapeutics, Inc.	Tyk2 degraders and uses thereof
CN114181097B (zh) *	2021-12-10	2024-05-14	广东嘉博制药有限公司	一种盐酸甲氧明的合成方法
AU2023233663A1 (en) *	2022-03-17	2024-09-05	Pfizer Inc.	Methods, dosage regimens, and compositions for treating hidradenitis
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
WO2023213801A1 (en)	2022-05-02	2023-11-09	Precirix N.V.	Pre-targeting
CN118005609A (zh) *	2022-11-09	2024-05-10	沈阳药科大学	2-氨基嘧啶类化合物及其用途
WO2024148186A1 (en) *	2023-01-04	2024-07-11	Aerie Pharmaceuticals, Inc.	Polymorphs of a jak1/tyk2 inhibitor and uses thereof
WO2024148184A1 (en) *	2023-01-04	2024-07-11	Aerie Pharmaceuticals, Inc.	Compounds and processes for the preparation of jak inhibitors
CN116396298A (zh) *	2023-06-06	2023-07-07	四川维亚本苑生物科技有限公司	CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法
CN116903592A (zh) *	2023-07-13	2023-10-20	特科罗生物科技(成都)有限公司	一种嘧啶胺类nuak抑制剂及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4131139A1 (de)	1991-09-19	1993-03-25	Bayer Ag	Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
JP4891068B2 (ja)	2004-03-31	2012-03-07	第一三共株式会社	１，２−シス−２−フルオロシクロプロパン−１−カルボン酸エステル類の製造法
WO2006109846A1 (ja)	2005-04-06	2006-10-19	Takeda Pharmaceutical Company Limited	トリアゾール誘導体およびその用途
WO2007042298A1 (en)	2005-10-13	2007-04-19	Glaxo Group Limited	Pyrrolopyrimidine derivatives as syk inhibitors
NL2000323C2 (nl) *	2005-12-20	2007-11-20	Pfizer Ltd	Pyrimidine-derivaten.
CN104650077A (zh) *	2006-01-17	2015-05-27	沃泰克斯药物股份有限公司	适用作詹纳斯激酶抑制剂的吖吲哚类
US20090270390A1 (en) *	2006-09-14	2009-10-29	Astrazeneca	Pyrimidine derivatives
WO2008032033A1 (en) *	2006-09-14	2008-03-20	Astrazeneca Ab	4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CL2008000467A1 (es) *	2007-02-14	2008-08-22	Janssen Pharmaceutica Nv	Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
JP2010523522A (ja) *	2007-04-02	2010-07-15	パラウ・フアルマ・ソシエダツド・アノニマ	Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
US8188083B2 (en)	2007-06-28	2012-05-29	Abbott Laboratories	Triazolopyridazines
US8076491B2 (en)	2007-08-21	2011-12-13	Senomyx, Inc.	Compounds that inhibit (block) bitter taste in composition and use thereof
JP5368556B2 (ja)	2008-07-16	2013-12-18	エフ．ホフマン−ラロシュアーゲー	心臓血管疾患の処置のための新規ヘテロシクリル化合物
WO2010075273A1 (en)	2008-12-23	2010-07-01	Schering Corporation	Bicyclic heterocycle derivatives and methods of use thereof
CN102574857B (zh) *	2009-07-08	2015-06-10	利奥制药有限公司	作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
US9040545B2 (en)	2010-08-20	2015-05-26	Cellzome Limited	Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
WO2013043962A1 (en)	2011-09-22	2013-03-28	Merck Sharp & Dohme Corp.	Cyanomethylpyrazole carboxamides as janus kinase inhibitors
WO2013090837A2 (en)	2011-12-16	2013-06-20	Invista North America S.A.R.L.	METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE
HUE046057T2 (hu)	2014-08-21	2020-02-28	Boehringer Ingelheim Int	Új spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és származékok, mint MDM2-P53-inhibitorok
NO2721710T3 (de)	2014-08-21	2018-03-31

2012
- 2012-06-19 NO NO12803361A patent/NO2721710T3/no unknown
2015
- 2015-08-07 ME MEP-2017-284A patent/ME02856B/de unknown
- 2015-08-07 RS RS20180079A patent/RS56807B1/sr unknown
- 2015-08-07 PT PT157666272T patent/PT3183247T/pt unknown
- 2015-08-07 AU AU2015304883A patent/AU2015304883B2/en active Active
- 2015-08-07 MY MYPI2017700538A patent/MY192109A/en unknown
- 2015-08-07 MX MX2017002241A patent/MX2017002241A/es active IP Right Grant
- 2015-08-07 KR KR1020177007276A patent/KR101877189B1/ko active IP Right Grant
- 2015-08-07 UA UAA201701672A patent/UA117976C2/uk unknown
- 2015-08-07 CU CU2017000015A patent/CU24435B1/es unknown
- 2015-08-07 EP EP15766627.2A patent/EP3183247B9/de active Active
- 2015-08-07 LT LTEP15766627.2T patent/LT3183247T/lt unknown
- 2015-08-07 AP AP2017009748A patent/AP2017009748A0/en unknown
- 2015-08-07 SG SG11201700957WA patent/SG11201700957WA/en unknown
- 2015-08-07 PL PL15766627T patent/PL3183247T3/pl unknown
- 2015-08-07 NZ NZ729005A patent/NZ729005A/en unknown
- 2015-08-07 DK DK15766627.2T patent/DK3183247T3/en active
- 2015-08-07 SI SI201530156T patent/SI3183247T1/en unknown
- 2015-08-07 EA EA201700077A patent/EA032609B1/ru unknown
- 2015-08-07 CN CN201580057140.5A patent/CN107074867B/zh active Active
- 2015-08-07 WO PCT/IB2015/056021 patent/WO2016027195A1/en active Application Filing
- 2015-08-07 CR CR20170066A patent/CR20170066A/es unknown
- 2015-08-07 JP JP2017509666A patent/JP6218260B2/ja active Active
- 2015-08-07 HU HUE15766627A patent/HUE035553T2/hu unknown
- 2015-08-07 GE GEAP201514430A patent/GEP20197003B/en unknown
- 2015-08-07 ES ES15766627.2T patent/ES2655971T3/es active Active
- 2015-08-07 MA MA040587A patent/MA40587A/fr unknown
- 2015-08-07 PE PE2017000248A patent/PE20171177A1/es unknown
- 2015-08-07 TN TN2017000044A patent/TN2017000044A1/en unknown
- 2015-08-07 BR BR112017003054-3A patent/BR112017003054B1/pt active IP Right Grant
- 2015-08-07 MD MDA20170016A patent/MD4800C1/ro active IP Right Grant
- 2015-08-18 CA CA2900855A patent/CA2900855C/en active Active
- 2015-08-19 UY UY0001036275A patent/UY36275A/es active IP Right Grant
- 2015-08-19 US US14/829,753 patent/US9663526B2/en active Active
- 2015-08-20 TW TW104127204A patent/TWI583681B/zh active
- 2015-08-20 AR ARP150102681A patent/AR101599A1/es active IP Right Grant
2017
- 2017-02-09 ZA ZA2017/01005A patent/ZA201701005B/en unknown
- 2017-02-14 PH PH12017500276A patent/PH12017500276A1/en unknown
- 2017-02-16 SV SV2017005384A patent/SV2017005384A/es unknown
- 2017-02-16 EC ECIEPI201710156A patent/ECSP17010156A/es unknown
- 2017-02-17 CO CONC2017/0001603A patent/CO2017001603A2/es unknown
- 2017-02-20 CL CL2017000406A patent/CL2017000406A1/es unknown
- 2017-02-20 NI NI201700020A patent/NI201700020A/es unknown
- 2017-02-21 DO DO2017000048A patent/DOP2017000048A/es unknown
- 2017-02-21 GT GT201700035A patent/GT201700035A/es unknown
- 2017-02-21 IL IL250709A patent/IL250709B/en active IP Right Grant
- 2017-05-03 US US15/585,626 patent/US10463675B2/en active Active
- 2017-12-11 HR HRP20171913TT patent/HRP20171913T1/hr unknown
2018
- 2018-01-10 CY CY20181100036T patent/CY1119771T1/el unknown
2019
- 2019-09-24 US US16/580,667 patent/US10980815B2/en active Active
2020
- 2020-07-02 US US16/920,027 patent/US11197867B2/en active Active
2021
- 2021-08-06 US US17/396,094 patent/US20210377495A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NI201700020A (es)	2017-05-02
RS56807B1 (sr)	2018-04-30
US20200038409A1 (en)	2020-02-06
CO2017001603A2 (es)	2017-05-10
CN107074867B (zh)	2019-10-22
CN107074867A (zh)	2017-08-18
CA2900855A1 (en)	2016-02-21
NZ729005A (en)	2020-06-26
CU20170015A7 (es)	2017-06-05
TWI583681B (zh)	2017-05-21
US20200330477A1 (en)	2020-10-22
WO2016027195A1 (en)	2016-02-25
IL250709A0 (en)	2017-04-30
MD4800B1 (ro)	2022-03-31
LT3183247T (lt)	2018-01-25
UA117976C2 (uk)	2018-10-25
SG11201700957WA (en)	2017-03-30
EP3183247B9 (de)	2018-07-25
HUE035553T2 (hu)	2018-05-02
JP2017524022A (ja)	2017-08-24
MY192109A (en)	2022-07-27
DK3183247T3 (en)	2018-01-15
CU24435B1 (es)	2019-09-04
ES2655971T3 (es)	2018-02-22
IL250709B (en)	2019-05-30
EA201700077A1 (ru)	2017-07-31
AU2015304883A1 (en)	2017-03-02
PH12017500276A1 (en)	2017-07-03
MD4800C1 (ro)	2022-10-31
ES2655971T9 (es)	2018-09-14
MA40587A (fr)	2017-06-28
JP6218260B2 (ja)	2017-10-25
ZA201701005B (en)	2019-07-31
AR101599A1 (es)	2016-12-28
MD20170016A2 (ro)	2017-08-31
SV2017005384A (es)	2017-07-10
AU2015304883B2 (en)	2018-05-10
ECSP17010156A (es)	2017-11-30
EA032609B1 (ru)	2019-06-28
SI3183247T1 (en)	2018-02-28
KR101877189B1 (ko)	2018-07-10
UY36275A (es)	2016-04-01
DOP2017000048A (es)	2017-06-30
KR20170036109A (ko)	2017-03-31
US20160052930A1 (en)	2016-02-25
CR20170066A (es)	2017-07-17
PT3183247T (pt)	2018-01-18
PE20171177A1 (es)	2017-08-22
US9663526B2 (en)	2017-05-30
GEP20197003B (en)	2019-07-25
EP3183247A1 (de)	2017-06-28
MX2017002241A (es)	2017-05-03
US10980815B2 (en)	2021-04-20
TW201609706A (zh)	2016-03-16
CY1119771T1 (el)	2018-06-27
US20210377495A1 (en)	2021-12-02
TN2017000044A1 (en)	2018-07-04
ME02856B (de)	2018-04-20
US10463675B2 (en)	2019-11-05
PL3183247T3 (pl)	2018-03-30
CA2900855C (en)	2022-03-15
HRP20171913T1 (hr)	2018-02-09
AP2017009748A0 (en)	2017-02-28
BR112017003054B1 (pt)	2023-04-11
US11197867B2 (en)	2021-12-14
EP3183247B1 (de)	2017-11-29
GT201700035A (es)	2019-10-10
CL2017000406A1 (es)	2017-10-06
US20170239264A1 (en)	2017-08-24
BR112017003054A2 (pt)	2017-11-21

Publication	Publication Date	Title
BR112014017635A2 (de)	2017-06-20
BR112014017614A2 (de)	2017-06-20
NO2721710T3 (de)	2018-03-31
BR112014017625A2 (de)	2017-06-20
BR112014017592A2 (de)	2017-06-20
BR112014017659A2 (de)	2017-06-20
BR112014017646A2 (de)	2017-06-20
BR112014017638A2 (de)	2017-06-20
BR112014017607A2 (de)	2017-06-20
BR112014020054A2 (de)	2017-06-20
BR112013027865A2 (de)	2017-01-03
BR112014017634A2 (de)	2017-06-20
BR112014017609A2 (de)	2017-06-20
BR112014017644A2 (de)	2017-06-20
BR112014017588A2 (de)	2017-06-20
BR112014017647A2 (de)	2017-06-20
BR112014013184A8 (de)	2017-06-27
BR112014017618A2 (de)	2017-06-20
BR112014017630A2 (de)	2017-06-20
BR112014017652A2 (de)	2017-06-20
BR112014017621A2 (de)	2017-06-20
BR112014017622A2 (de)	2017-06-20
BR112014017627A2 (de)	2017-06-20
BR112014017623A2 (de)	2017-06-20
BR112014017631A2 (de)	2017-06-20